Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article

Che-Yung Chao,Robert Battat,Alex Al Khoury,Sophie Restellini,Giada Sebastiani,Talat Bessissow

DOI: https://doi.org/10.3748/wjg.v22.i34.7727

IF: 5.374

2016-01-01

World Journal of Gastroenterology

Abstract:Emerging data have highlighted the co-existence of non-alcoholic fatty liver disease (NAFLD) and inflammatory bowel disease; both of which are increasingly prevalent disorders with significant complications and impact on future health burden. Cross-section observational studies have shown widely variable prevalence rates of co-existing disease, largely due to differences in disease definition and diagnostic tools utilised in the studies. Age, obesity, insulin resistance and other metabolic conditions are common risks factors in observational studies. However, other studies have also suggested a more dominant role of inflammatory bowel disease related factors such as disease activity, duration, steroid use and prior surgical intervention, in the development of NAFLD. This suggests a potentially more complex pathogenesis and relationship between the two diseases which may be contributed by factors including altered intestinal permeability, gut dysbiosis and chronic inflammatory response. Commonly used immunomodulation agents pose potential hepatic toxicity, however no definitive evidence exist linking them to the development of hepatic steatosis, nor are there any data on the impact of therapy and prognosis in patient with co-existent diseases. Further studies are required to assess the impact and establish appropriate screening and management strategies in order to allow early identification, intervention and improve patient outcomes.

gastroenterology & hepatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the co - existence phenomenon of non - alcoholic fatty liver disease (NAFLD) and inflammatory bowel disease (IBD). Specifically, the paper focuses on the following aspects:

1. **Epidemiology**: Explore the prevalence of NAFLD in IBD patients. The prevalence of NAFLD reported in different studies varies greatly, mainly due to different disease definitions and diagnostic tools.

2. **Risk factors**: Analyze the risk factors of NAFLD in IBD patients. Common risk factors include age, obesity, insulin resistance and other metabolic conditions. In addition, IBD - related factors such as disease activity, disease duration, the use of corticosteroids and previous surgical interventions also play an important role in the development of NAFLD.

3. **Clinical significance**: Discuss the clinical significance of the co - existence of NAFLD and IBD, including screening, diagnosis and treatment strategies. At present, there is a lack of specific screening guidelines and management strategies for NAFLD in IBD patients.

4. **Pathological mechanism**: Explore the potential pathological mechanisms of the co - existence of NAFLD and IBD, including changes in intestinal permeability, intestinal flora imbalance and chronic inflammatory response, etc.

Through the exploration of these aspects, the paper aims to provide a scientific basis for early identification, intervention and improvement of the prognosis of patients with co - existing diseases.